KF 31327

Drug Profile

KF 31327

Latest Information Update: 21 Jan 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyowa Hakko
  • Developer Kyowa Hakko Kirin
  • Class Quinazolines; Small molecules; Thiones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Erectile dysfunction

Most Recent Events

  • 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin
  • 01 Jul 2004 KF 31327 is available for licensing (http://www.kyowa.co.jp/eng/)
  • 04 Feb 2003 A preclinical study has been added to the Mens Health pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top